Cellogen Therapeutics Raises $2M From Kotak Alternate Asset Managers

Why It Matters

The investment underscores growing private capital confidence in affordable cell‑therapy platforms and could accelerate access to lower‑cost cancer treatments in emerging markets.

Key Takeaways

• Cellogen secured $2 M from Kotak Alts to expand CAR‑T pipeline.
• Dual‑antigen CAR‑T platform aims to cut therapy cost to $60‑70K.
• Funding follows Natco Pharma’s 5% stake purchase for $1.8 M.
• Kotak Life Sciences Fund I has raised $29 M for life‑science startups.
• India’s biotech ecosystem hosts over 11,000 startups, boosted by SHAKTI scheme.

Pulse Analysis

Cellogen Therapeutics, a Hyderabad‑based biotech founded in 2021, announced a ₹20 crore ($2 million) investment from Kotak Alternate Asset Managers through its Life Sciences Fund I. The capital will accelerate the company’s CAR‑T clinical programs, expand a dual‑antigen platform, and upgrade GMP‑compliant manufacturing. By targeting two cancer markers simultaneously, Cellogen hopes to improve efficacy and lower relapse rates compared with single‑antigen CAR‑T therapies. Crucially, the startup plans to price treatments at $60‑70 k, a fraction of the $500‑700 k price tag of existing products, aiming to broaden patient access.

The infusion comes after Natco Pharma bought a 5% stake in Cellogen for roughly $1.8 million, underscoring growing corporate interest in early‑stage gene‑therapy firms. Kotak’s Life Sciences Fund I, which closed at $29 million, has already backed ventures such as ZeroHarm Sciences, which raised $7.2 million for overseas expansion. These deals reflect a broader surge in Indian biotech financing; the sector now hosts more than 11,000 startups and benefits from the government’s Biopharma SHAKTI scheme announced in the recent Union Budget. Together, private capital and policy support are reshaping the country’s life‑science landscape.

Cellogen’s dual‑antigen CAR‑T approach could give it a competitive edge as global demand for affordable cell therapies rises. If the company clears Phase I trials with CMC Vellore, it may attract follow‑on funding and strategic partnerships, potentially accelerating time‑to‑market. Lower‑cost pricing also aligns with emerging markets’ need for scalable oncology solutions, positioning India as a hub for cost‑effective biotech innovation. Investors will watch closely whether Cellogen can translate its technology into commercial products, a success that could validate the country’s burgeoning life‑science ecosystem.

Deal Summary

Biotech startup Cellogen Therapeutics secured ₹20 Cr (≈$2 M) in funding from Kotak Alternate Asset Managers via its Kotak Life Sciences Fund I. The capital will support the company’s CAR‑T clinical programmes, gene‑therapy pipeline, and GMP‑compliant manufacturing and regulatory capabilities.